Invention Grant
- Patent Title: Crystal of pyrrolidine compound
-
Application No.: US17418563Application Date: 2019-12-27
-
Publication No.: US12077524B2Publication Date: 2024-09-03
- Inventor: Naoko Ueda , Hiroomi Nagata , Takahiro Yoshida
- Applicant: MITSUBISHI TANABE PHARMA CORPORATION
- Applicant Address: JP Osaka
- Assignee: MITSUBISHI TANABE PHARMA CORPORATION
- Current Assignee: MITSUBISHI TANABE PHARMA CORPORATION
- Current Assignee Address: JP Osaka
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Priority: JP 18247437 2018.12.28
- International Application: PCT/JP2019/051570 2019.12.27
- International Announcement: WO2020/138481A 2020.07.02
- Date entered country: 2021-06-25
- Main IPC: C07D401/14
- IPC: C07D401/14

Abstract:
The present invention provides a crystal of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid having a certain quality that can be used as a drug substance. Specifically, the present invention provides a crystal comprising an equimolar amount of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid and phosphoric acid.
Public/Granted literature
- US20220073497A1 CRYSTAL OF PYRROLIDINE COMPOUND Public/Granted day:2022-03-10
Information query